Journal of Wound Care - Trial Subscription

Get your first 3 issues for only £3!

Peer-reviewed, and internationally focused, Journal of Wound Care (JWC) is the only monthly publication publishing up-to-date original research and clinical information on everything related to tissue viability. Medline-listed with an Impact Factor, it is an official partner of both the European Wound Management Association (EWMA) and the World Union of Wound Healing Societies (WUWHS) - testament to its quality and relevance to practice worldwide. JWC supports the professional development of specialist wound care practitioners by establishing a strong evidence base to inform advanced clinical knowledge and skills.

Subscribing will enable you to:

  • Stay up-to-date with current thinking and best practice in tissue viability
  • Maintain and update your knowledge and skills in key clinical areas
  • Reflect on your learning and support your continuing professional development

Trial subscription offer

Subscribe now and get your first 3 issues for only £3 - a saving of over 89% on our normal rate. Try Journal of Wound Care today and discover how we can help you in practice. We are sure you won't be disappointed - but you can cancel your subscription anytime.

*£3 for the first three issues of your subscription. Price will revert to standard rate of £29.00 per quarter thereafter. Payment taken by Direct Debit every three months.

 

Journal of Wound Care Print £3 for 3 issues

SAVE 89%

Latest print issues

Wound Care Handbook

CPD Launchpad

From £3.00

Journal of Wound Care Website £3 for 3 months

SAVE 89%

Online archive access

Wound Care Handbook

CPD Launchpad

From £3.00

Money-back guarantee. If – for whatever reason – you are not happy with the first issue you receive, our 30 day money-back guarantee means we will offer you a full refund, so you have nothing to lose. The first issue will be yours to keep.

Institutional subscriptions. Click here for information regarding our institutional rates for universities and private or public companies.